The GuardianThe Guardian

AstraZeneca CEO links Europe’s Covid surge to rejection of its vaccine

By Linda Geddes

23 Nov 2021 · 3 min read

Scientists have reacted with scepticism to claims by AstraZeneca’s CEO that low uptake of the Oxford/AstraZeneca jab among elderly Europeans could explain the current surge in Covid-19 infections in mainland Europe.

Pascal Soriot told BBC Radio 4’s Today programme that differences in T-cell immunity between the vaccines might mean that those who received the Oxford/AstraZeneca jab had longer-lasting immune protection against the virus. T- cells are a class of immune cells that educate antibody-producing B cells about the nature of the viral threat and directly kill infected cells.

Sign in to informed

  • Curated articles from premium publishers, ad-free
  • Concise Daily Briefs with quick-read summaries
  • Read, listen, save for later, or enjoy offline
  • Enjoy personalized content
Or

LoginForm.agreeToTerms